 Imara Inc. IMRA, a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it was added as a member of the U.S. small-cap Russell 2000 Index, effective after the U.S. market opens on July 1, as part of the 2020 Russell U.S. Indexes reconstitution. Membership in the Russell 2000 Index, which remains in place for one year, is based on membership in the broad-market Russell 3000 Index. We are pleased to be added to the Russell 2000 Index following our successful IPO in March and the progress weve made in the months since, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. 